No Massive FDA/NIH 'Cures' Overhaul At Senate
This article was originally published in Scrip
Rather than releasing a massive draft piece of legislation aimed at overhauling the US biomedical enterprise, like the House Energy and Commerce Committee did a year ago – proposing big changes to the FDA and the National Institutes of Health (NIH) – the Senate Health, Education, Labor and Pensions (HELP) Committee has settled on taking a "step-by-step" approach.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.